S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
As Musk is learning, content moderation is a messy job
FDA change ushers in cheaper, easier-to-get hearing aids
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Reformers take 6 of 14 UAW board seats, could win majority
OPEC keeps oil targets amid uncertainty on Russian sanctions
NASDAQ:RDHL

RedHill Biopharma - RDHL Stock Forecast, Price & News

$0.27
-0.10 (-27.21%)
(As of 12/2/2022 09:00 PM ET)
Add
Compare
Today's Range
$0.25
$0.28
50-Day Range
$0.27
$0.70
52-Week Range
$0.25
$3.37
Volume
8.62 million shs
Average Volume
1.89 million shs
Market Capitalization
$14.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

RedHill Biopharma MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.34mentions of RedHill Biopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.65) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.29 out of 5 stars

Medical Sector

996th out of 1,033 stocks

Pharmaceutical Preparations Industry

484th out of 502 stocks

RDHL stock logo

About RedHill Biopharma (NASDAQ:RDHL) Stock

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

RDHL Stock News Headlines

RDHL RedHill Biopharma Ltd.
Redhill Biopharma Ltd.
See More Headlines
Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

RDHL Company Calendar

Last Earnings
11/30/2021
Today
12/05/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RDHL
Employees
201
Year Founded
N/A

Profitability

Net Income
$-97,740,000.00
Net Margins
-116.69%
Pretax Margin
-116.69%

Debt

Sales & Book Value

Annual Sales
$85.76 million
Book Value
($0.87) per share

Miscellaneous

Free Float
49,096,000
Market Cap
$14.00 million
Optionable
Optionable
Beta
1.97

Key Executives

  • Mr. Dror Ben-Asher (Age 56)
    Co-Founder, Chairman & CEO
    Comp: $884.67k
  • Mr. Micha Ben-Chorin (Age 53)
    Chief Financial Officer
    Comp: $548.14k
  • Mr. Gilead Raday MPhil (Age 47)
    MSc, Chief Operating Officer
    Comp: $539.74k
  • Mr. Adi Frish (Age 52)
    Chief Corp. & Bus. Devel. Officer
    Comp: $519.65k
  • Mr. Rick D. Scruggs (Age 62)
    Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director
    Comp: $736.35k
  • Dr. Mark L. Levitt M.D.
    Ph.D., Chief Scientific Officer
  • Ms. Alexandra Okmian
    Sr. Bus. Devel. & Investor Relations Mang.
  • Kristin Comer
    VP, Gen. Counsel & Chief Compliance Officer
  • Ms. Valerie Graceffa
    VP of Sales
  • Mr. Rob Jackson
    Sr. VP of Sales & Marketing













RDHL Stock - Frequently Asked Questions

How have RDHL shares performed in 2022?

RedHill Biopharma's stock was trading at $2.58 at the start of the year. Since then, RDHL stock has decreased by 89.7% and is now trading at $0.2657.
View the best growth stocks for 2022 here
.

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) issued its quarterly earnings results on Tuesday, November, 30th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.02. The biotechnology company had revenue of $21.61 million for the quarter, compared to the consensus estimate of $23.41 million. RedHill Biopharma had a negative trailing twelve-month return on equity of 9,208.02% and a negative net margin of 116.69%. During the same quarter in the previous year, the company posted ($0.50) earnings per share.

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).

What is RedHill Biopharma's stock symbol?

RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."

Who are RedHill Biopharma's major shareholders?

RedHill Biopharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.12%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%).

How do I buy shares of RedHill Biopharma?

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RedHill Biopharma's stock price today?

One share of RDHL stock can currently be purchased for approximately $0.27.

How much money does RedHill Biopharma make?

RedHill Biopharma (NASDAQ:RDHL) has a market capitalization of $14.00 million and generates $85.76 million in revenue each year. The biotechnology company earns $-97,740,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does RedHill Biopharma have?

The company employs 201 workers across the globe.

How can I contact RedHill Biopharma?

RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The official website for the company is www.redhillbio.com. The biotechnology company can be reached via phone at 972-3541-3131, via email at investors@redhillbio.com, or via fax at 972-3541-3144.

This page (NASDAQ:RDHL) was last updated on 12/5/2022 by MarketBeat.com Staff